MEI Pharma: MEI Pharma Reports Initial Data from Clinical Study Evaluating ME-344 in Combination with Bevacizumab (Avastin) in Relapsed Metastatic Colorectal Cancer Patients

(marketscreener.com) - Cohort 1 Exceeds Predetermined Non-Progression Threshold in the Ongoing Phase 1b Study - - ME-344 in Combination with Bevacizumab was Generally Well-tolerated with no Evidence of Overlapping Toxicity - - MEI to Continue Advancing ME-344 via Development of a New Formulation with the Potential to Increase...https://www.marketscreener.com/quote/stock/MEI-PHARMA-INC-12212540/news/MEI-Pharma-Reports-Initial-Data-from-Clinical-Study-Evaluating-ME-344-in-Combination-with-Bevacizuma-46413942/?utm_medium=RSS&utm_content=20240411